Biogen, Inc. (NASDAQ/BGEN) today announced that Burt Adelman, M.D., has been appointed Executive Vice President, Research and Development. Dr. Adelman reports to James C. Mullen, President and Chief Executive Officer.
Dr. Adelman is most recently Biogen’s Vice President of Medical Research. He joined Biogen in 1991 as Director of Medical Research and has held positions of increasing responsibility including, Vice President, Development Operations overseeing the Preclinical Development, Medical Operations and Regulatory Affairs groups and Vice President, Regulatory Affairs. Since 1992 Dr. Adelman has held an appointment as a Lecturer of Medicine at Harvard Medical School.
In his new position as Executive Vice President of Research and Development, Dr. Adelman’s specific global functional areas of responsibility include all of medical research, including clinical and preclinical activities; all research, including drug discovery; and worldwide regulatory affairs.
Prior to joining Biogen, Dr. Adelman was Associate Professor of Medicine, at the Medical College of Virginia, Virginia Commonwealth University and Chief of the Hematology Service, Hunter Holmes McGuire Department of Veteran’s Affairs Medical Center in Richmond, Virginia. Dr. Adelman has also been an Instructor of Medicine at Harvard Medical School and a member of the Hematology/Oncology Division of the Department of Medicine, Brigham & Women’s Hospital in Boston. He received his B.S. from Trinity College and earned his M.D. from Cornell Medical College.
Mr. Mullen said, “Burt’s promotion acknowledges the tremendous contributions he has made to Biogen’s world class research and patient focused solutions. He has demonstrated exceptional leadership in each of his positions at Biogen and will continue to play an instrumental role in driving the growth of Biogen to a multi-product company with important novel therapeutics.”
Biogen, Inc., winner of the U.S. National Medal of Technology, is a biopharmaceutical company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge, MA, the Company’s revenues are generated from international sales of AVONEX® (Interferon beta-1a) for treatment of relapsing forms of
multiple sclerosis, and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen’s research and development activities are focused on novel products to treat inflammatory and autoimmune diseases, neurological diseases, cancer, fibrosis and congestive heart failure. The Company maintains active clinical research programs in protein therapeutics, small molecules, genomics and gene therapy. For copies of press releases and additional information about the Company, please consult Biogen’s Homepage on the World Wide Web at http://www.biogen.com